The FDA move follows a determination that the disease constitutes a serious health challenge for patients from birth through age 18. VCA-894A, an antisense oligonucleotide therapy, targets the underlying mechanisms of the disorder, which typically manifests as severe muscle weakness and a gradual loss of motor function.

By securing this designation, Vanda gains a strategic foothold in the pediatric treatment landscape. If the therapy eventually receives full regulatory approval, the company may become eligible for a priority review voucher, a valuable asset that can be used to expedite the evaluation of future drug applications or sold to other developers.